Background: Bronchiolitis is a common viral lower respiratory tract infection predominantly affecting children under two years of age, with Respiratory Syncytial Virus (RSV) responsible for up to 80% of cases in the United Kingdom. Diagnosis is primarily clinical, with children presenting with coryzal symptoms progressing to cough, feeding difficulty and fever. NICE recommends supportive care as the primary treatment and advises against the routine use of antibiotics, steroids, inhaled bronchodilators, and chest X-rays, yet non-adherence to these recommendations persists in clinical practice. In older children, diagnostic certainty is further reduced and RSV positivity alone does not confirm bronchiolitis, creating both a clinical and antimicrobial stewardship challenge in an age group where limited age-specific guidance creates further clinical uncertainty. NICE recommends considering other diagnoses, including viral-induced wheeze or early-onset asthma in this age group, particularly where there is recurrent wheeze, absence of crackles, or a personal or family history of atopy. This audit aimed to evaluate whether RSV-positive children aged over two years were managed supportively, and if prescribed antibiotics, to identify clinical factors associated with antibiotic prescribing in this cohort.
Methods: A single-center retrospective audit was conducted at the Royal Devon and Exeter Hospital, United Kingdom. In total, 83 patients aged over two years who tested RSV-positive and presented to the pediatric department between October 2024 and February 2025 were identified via the EPIC electronic patient record system. Data were extracted on demographics, risk factors, clinical presentation, investigations, management, and outcomes.
Results: 44.6% of RSV-positive children aged over two years were prescribed antibiotics, despite NICE recommending supportive care as the primary approach to treatment. 45.8% of patients required inpatient admission. Fever (64.9%), respiratory distress (59.5%), and chest X-ray findings were the clinical findings most strongly associated with antibiotic prescribing. Notably, 51.4% of antibiotic-prescribed patients had a chest X-ray performed despite this not being routinely recommended by NICE, with 94.7% showing abnormalities. Such findings are well recognized to mimic pneumonia rather than confirm it, and should not be used to guide antibiotic prescribing in suspected bronchiolitis. Critically, 70.3% of patients prescribed antibiotics had no blood tests performed, meaning the majority of prescriptions were made without any supporting inflammatory markers. 62.1% of antibiotic prescriptions were initiated by Tier 1 clinicians. Broader guideline non-adherence was also evident, with 42.2% of patients receiving inhalers or nebulizers and 31.3% receiving steroids, neither of which is routinely recommended by NICE in bronchiolitis.
Conclusions: This audit reveals substantial guideline non-adherence in the management of RSV-positive children aged over two years, with nearly half receiving antibiotics, many without objective evidence of bacterial infection. Diagnostic uncertainty in this age group, where bronchiolitis, viral-induced wheeze, and early-onset asthma overlap, is a key driver, but cannot alone account for the breadth of non-adherence observed.
Key recommendations arising from this audit include the following. Targeted education for Tier 1 clinicians on differential diagnosis, antimicrobial stewardship, and the appropriate use of investigations in this age group is recommended. Antibiotic prescribing should be supported by documented clinical justification, and improved recording of atopy history, smoking exposure, and examination findings will be essential for future audit cycles. These findings highlight a broader challenge in paediatric antimicrobial stewardship: diagnostic uncertainty, without targeted education and clear local guidance, risks driving antibiotic overuse in a population where the evidence base remains limited.

